在固体瘤中准HER2:揭示结构和新型表位
Xinlin Liu1, Yunlong Song2, Panpan Cheng2
1The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao 266071, China; Qingdao Cancer Institute, Qingdao 266071, China.
Cancer treatment reviews
|September 13, 2024
概括
本综述探讨了针对人体表皮生长因子受体-2 (HER2) 的向疗法,重点关注抗体-药物合物 (ADC) 和通过分析 HER2 结构和抗体表位来克服治疗耐药性的策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 免疫学 免疫学 免疫学
背景情况:
- 人体表皮生长因子受体-2 (HER2) 是固体瘤的关键标,HER2向治疗显著改善了生存率.
- 对当前抗HER2治疗的耐药性仍然是一个重大的临床挑战.
- 复杂的结构和HER2的二分化为开发新的向药物带来了困难.
研究的目的:
- 审查 HER2.2 的结构复杂性.
- 为 HER2 向抗体及其衍生物提供表位特征的概述.
- 探索抗体表位,功能和抗药性瘤中的疗效之间的联系.
主要方法:
- 文献综述综合了关于HER2结构和向治疗的当前研究.
- 对HER2向抗体的表位特征的分析.
- 表皮质结合与治疗疗效的相关性,特别是在耐药的HER2阳性癌症中.
主要成果:
- 详细了解HER2的结构动态和二元化.
- HER2抗体表位和它们的功能影响的全面映射.
- 有证据表明,特定的表位与抵抗性HER2-阳性瘤的改善结果有关.
结论:
- 了解HER2结构和抗体表位对于开发有效疗法至关重要.
- 针对特定或不重叠的表位提供了克服抵抗的潜力.
- 新兴的针对独特部位的抗HER2药物可能会彻底改变对HER2阳性癌症的治疗.
更多相关视频
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
16.7K
11:34Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
Published on: December 5, 2017
12.6K
相关概念视频
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
02:38Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K